Mechanism of Action
Stress Axis Modulation
TCAP-1 reduces CRF receptor sensitivity and dampens CRF-induced HPA axis responses without directly antagonizing the CRF receptor. It activates beta-arrestin signaling pathways and downregulates CRF receptor surface expression through receptor internalization. This modulatory mechanism may allow TCAP to attenuate chronic stress responses without fully blocking the acute stress reaction.
Neuronal Cytoskeletal Effects
TCAP promotes neuronal process formation and stabilizes the actin cytoskeleton through interactions with dystroglycan complexes. In hippocampal neurons, TCAP treatment increases dendritic complexity and spine density. These structural effects may underlie its ability to improve cognitive resilience to stress and promote neuroplasticity.
Research Summary
Anxiety and PTSD Models
PreclinicalRepeated subcutaneous TCAP-1 administration reduces acoustic startle responses, contextual fear conditioning, and CRF-induced anxiety in rodents. Notably, TCAP-1 effects persist for weeks after the last injection, suggesting long-term neuroplastic changes. These properties support exploration in PTSD and anxiety disorder models.
Neuroprotection
PreclinicalTCAP-1 protects hippocampal neurons against ischemic and oxidative damage. It reduces reactive oxygen species, activates Nrf2/antioxidant pathways, and promotes mitochondrial integrity. The peptide also enhances glucose uptake in neurons through a dystroglycan-dependent mechanism, potentially improving neuronal metabolic resilience.
Calculate your TCAP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anxiety / PTSD model | 40 nmol/kg SC | Weekly x 4 weeks | Subcutaneous injection |
| Neuroprotection | 1-10 nM | Single | Cell culture / in vivo |
Preclinical only. No human clinical data for TCAP peptides.
Interactions
Safety Profile
TCAP-1 has an excellent preclinical safety profile with no observed adverse effects at effective doses in rodents. The prolonged behavioral effects from weekly dosing suggest tissue accumulation or long-lasting plasticity changes that require further characterization. No human pharmacokinetic or safety data available.
References
- [1]Bhatt DL et al. (2012). Teneurin C-terminal associated peptide (TCAP) reduces distress and anxiety in rats. Psychoneuroendocrinology, 37(3), 353-363.
- [2]Chand D et al. (2013). Biochemical and cell biological properties of the C-terminal region of teneurin-1. Biochemical Journal, 452(1), 63-73.